Table 2.

Safety of escalated doses of GNS561

Treatment-related AEs n (%)
Grade	1–2	3	Total
Nausea	13 (50)	−	13 (50)
Vomiting	14 (54)	−	14 (54)
Diarrhea	9 (35)	2 (8)	11 (42)
Decreased appetite	2 (8)	1 (4)	3 (12)
Abdominal pain	2 (8)	−	2 (8)
Abdominal distension	2 (8)	−	2 (8)
Constipation	1 (4)	−	1 (4)
Fever	1 (4)	−	1 (4)
Dyspepsia	1 (4)	−	1 (4)
Regurgitation	1 (4)	−	1 (4)
Weight decreased	1 (4)	−	1 (4)
Fatigue	5 (19)	1 (4)	6 (23)
Dizziness	1 (4)	−	1 (4)
Occasional weakness	1 (4)	−	1 (4)
Asthenia	1 (4)	1 (4)	2 (8)
Sweating	1 (4)	−	1 (4)
Blood zinc decreased	2 (8)	−	2 (8)
Anemia	1 (4)	−	1 (4)
ALT increased	−	1 (4)	1 (4)
AST increased	1 (4)	1 (4)	2 (8)
Increased bilirubin level	2 (8)	−	2 (8)
Blood albumin decreased	1 (4)	−	1 (4)
Hypertension	1 (4)	−	1 (4)
Dyspnea	1 (4)	−	1 (4)
Blurred vision	1 (4)	−	1 (4)
Hypercalcemia	1 (4)	−	1 (4)
Nephritic pain	1 (4)	−	1 (4)
Dry mouth	1 (4)	−	1 (4)
Cough	1 (4)	−	1 (4)
Peripheral sensory neuropathy	1 (4)	−	1 (4)
Mucosal inflammation	1 (4)	−	1 (4)